Following data from a small phase IIa study showing its experimental Alzheimer's disease (AD) therapy, PTI-125, led to decreases in key biomarkers of neuroinflammation and neurodegeneration, Cassava Sciences Inc. (formerly Pain Therapeutics) has dosed the first two patients in a phase IIb study of the candidate.